Immunotherapy in neuromuscular disorders: Current and future strategies

Muscle and Nerve

Volumn 19, Issue 10, 1996, Pages 1239-1251

  Drachman, Daniel B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anergy; autoimmunity; immune therapy; immunosuppression; myasthenia gravis; neuromuscular diseases; suppression; tolerance

Indexed keywords

AUTOANTIGEN; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ANTIGEN PRESENTING CELL; AUTOIMMUNITY; BONE MARROW DEPRESSION; DRUG THERAPY; HEADACHE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFERTILITY; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE IRRADIATION; MYASTHENIA GRAVIS; NEUROMUSCULAR DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; RADIOTHERAPY; REVIEW; T LYMPHOCYTE ACTIVATION; THERAPY;

AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; NEUROMUSCULAR DISEASES;

EID: 0029788252     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199610)19:10<1239::AID-MUS1>3.0.CO;2-F     Document Type: Review

References (69)

1. Abramsky O, Aharonov A, Webb C, Fuchs S: Cellular immune response to acetylcholine receptor rich fraction in patients with myasthenia gravis. Clin Exp Immunol 1975;19:11-16.
2. Ahmed AR, Hombal SM: Cyclophosphamide. A review of relevant pharmacology and clinical uses. J Am Acad Dermatol 1984;11:1115-1126.
3. Appel SH, Anwyl R, McAdams MW, Elias S: Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins. Proc Natl Acad Sci USA 1977;74:2130-2134.
4. Appel SH, Smith RG, Alexianu M, Engelhardt J, Stefani E: Autoimmunity as an etiological factor in sporadic amyotrophic lateral sclerosis, in Serratrice G, Munsat T (eds): Current Issues in the Pathogenesis and Therapy of ALS, 1995, pp 47-57.
5. Arsura E: Experience with intravenous immunoglobulins in myasthenia gravis. Clin Immunol Immunopathol 1989;53:S170.
6. Balcer LJ, McIntosh KR, NicholsJC, Drachman DB: Suppression of immune responses to acetylcholine receptor by interleukin 2-fusion toxin: in vivo and in vitro studies. J Neuroimmunol 1991;31:115-122.
7. Berzofsky JA, Brett SJ, Streicher HZ, Takahashi H: Antigen processing for presentation to lymphocytes: function, mechanisms, and implications for the T cell repertoire. Immunol Rev 1988;106:5-31.
8. Bitar DM, Whitacre CC: Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell Immunol 1988;112:364-370.
9. Breedveld FC: New perspectives on treating rheumatoid arthritis [editorial]. N Engl J Med 1995;333:183-184.
10. Brown JH, Jardetsky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC: Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-39.
11. Chen Y, Inobe JI, Marks R, Gonnella P, Kuchroo VK, Weiner HL: Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995;376:177-180.
12. Chesnut RW, Greg HM: Antigen presentation by B cells and its significance in T-B interactions. Adv Immunol 1986;39: 51-94.
13. Cocks BG, Chang C-CJ, Carballido JM, Yssel H, de Vries JE, Aversa G: A novel receptor involved in T-cell activation. Nature 1995;376:260-262.
14. Dalakas MC, Illa I, Dambrosio JM, et al.: A controlled trial of high dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
15. Dau PC, Lindstrom JM, Cassel CK, Clark EC: Plasmapheresis in myasthenia gravis and polymyositis, in Dau PC (ed): Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston, Houghton Mifflin, 1979, pp 229-247.
16. de Silva S, Blum JE, McIntosh KR, Order S, Drachman DB: Treatment of experimental myasthenia gravis with total lymphoid irradiation. Clin Immunol Immunopathol 1988;48:31-41.
17. Drachman DB: Myasthenia gravis. N Engl J Med 1994;330: 1797-1810.
18. Drachman DB: How to recognize an antibody-mediated autoimmune disease, in Waksman BH (ed): Immunologic Mechanisms in Neurologic and Psychiatric Disease. 1990, pp 183-186.
19. Drachman DB, Adams RN, Josifek JF, Self SG: Functional activities of anti-AChR autoantibodies and clinical severity of myasthenia gravis. N Engl J Med 1982;307:769-775.
20. Drachman DB, Adams RN, McIntosh K, Pestronk A: Treatment of experimental myasthenia gravis with cyclosporin A. Clin Immunol Immunopathol 1985;34:174-188.
21. Drachman DB, DeSilva S, Ramsay D, Pestronk A: Humoral pathogenesis of myasthenia gravis. Ann NY Acad Sci 1987;505: 90-104.
22. Drachman DB, Fishman PS, Rothstein JD, Motomura M, Lang B, Vincent A, Mellits ED: Amyotrophic lateral sclerosis: an autoimmune disease? II, in Serratrice G, Munsat TL (eds): Pathogenesis and Therapy of ALS, 1995.
23. Drachman DB, Okumura S, Adams RN, McIntosh KR: Oral tolerance in myasthenia gravis. Ann NY Acad Sci (in press).
24. Dwyer JM: Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-116.
25. Engel AG, Arahata K: The membrane attack complex of complement at the endplate in myasthenia gravis. Ann NY Acad Sci 1987;505:326-332.
26. Friedman A, Weiner HL: Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA 1994;91:6688-6692.
27. Fujii Y, Lindstrom J: Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. J Immunol 1988;140:1830-1837.
28. Handschumacher RE: Immunosuppressive agents, in Gilman AG, Rall TW, Nies AS, Taylor P (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. New York, Pergamon Press, 1990, pp 1264-1276.
29. Higgins PJ, Weiner HL: Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 1988;140:440-445.
30. Holoshitz J, Matitiau A, Cohen IR: Arthritis induced in rats by cloned T lymphocytes responsive to mycobacteria, but not to collagen type II. J Clin Invest 1984;73:211-215.
31. Kahn BD, Bach JF (eds): Proceedings of the Second International Congress on Cyclosporine. Transplant Proc 1988; 20(Suppl 3):1-1131.
32. Kao I, Drachman DB: Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science 1977;196: 527-529.
33. Killen JA, Lindstrom JM: Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates. J Immunol 1984;133: 2549-2553.
34. Kiyokawa T, Williams DP, Snider CE, Strom TB, Murphy JR: Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells. Protein Eng 1991;4:463-468.
35. Lambert EH, Lindstrom JM, Lennon VA: Endplate potentials in experimental autoimmune myasthenia gravis in rats. Ann NY Acad Sci 1976;274:300-318.
36. Lanzavecchia A: Antibody specific interactions between T and B cells. Nature 1985;314:537-539.
37. Lennon VA, Lindstrom JM, Seybold ME: Experimental autoimmune myasthenia gravis: cellular and humoral aspects. Ann NY Acad Sci 1976;274:283-299.
38. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-569.
39. Maron R, Zerubavel R, Friedman A, Cohen IR: T lymphocyte line specific for thyroglobulin produces or vaccinates against autoimmune thyroiditis in mice. J Immunol 1983;131:1316-1322.
40. Martin S, Drachman DB: Unpublished results.
41. Matell G: Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis. Ann NY Acad Sci 1987;505: 588-594.
42. McIntosh KR, Drachman DB: In preparation.
43. McIntosh KR, Linsley PJ, Drachman DB: Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis. Cell Immunol (in press).
44. McIntosh KR, Moran S, Adams RN, Drachman DB: In preparation.
45. McKhann GM, Griffin JW, Cornblath DR, Quaskey SA, Mellits ED: Role of therapeutic plasmapheresis in the acute Guillain-Barre syndrome. J Neuroimmunol 1988;20:297-230.
46. Melms A, Malcherek G, Gern U, Wiethoker H, Mueller CA, Schoepfer R, Lindstrom J: T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the α-subunit. Ann Neurol 1992;31:311-318.
47. Mokhtarian F, McFarlin DE, Raine CS: Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature 1984;309: 356-358.
48. Mowat AM: The regulation of immune responses to dietary protein antigens. Immunol Today 1987;8:93-98.
49. Nagler-Anderson C, Bober LA, Robinson ME, et al.: Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1986;83:7443-7446.
50. Newsom-Davis J, Harcourt G, Sommer N, Beeson D, Willcox N, Rothbard JB: T cell reactivity in myasthenia gravis. J Autoimmun 1989;2(suppl 2):101-108.
51. Noguchi SA, Drachman DB, Adams RN, Hirsch RL: Lymphocyte responsiveness to acetylcholine receptor in rats with experimental autoimmune myasthenia gravis. Ann Neurol 1980; 8:32-37.
52. Nussenblatt RB, Caspi RR, Mahdi R, et al.: Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol 1990; 144:1689-1695.
53. Okumura S, McIntosh K, Drachman DB: Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann Neurol 1994;36:704-713.
54. Pestronk A, Drachman DB, Teoh R, Adams RN: Combined short-term immunotherapy cures experimental autoimmune myasthenia gravis. Ann Neurol 1983;14:235-241.
55. Protti MP, Manfredi AA, Straub C, Wu XD, Howard JF, Conti-Tronconi BM: Use of synthetic peptides to establish antihuman acetylcholine receptor CD4+ cell lines from myasthenia gravis patients. J Immunol 1990;144:1711-1720.
56. Reim J, McIntosh KR, Drachman DB: Acetylcholine receptor presentation by B cells using heterobifunctional antibody conjugates. Ann NY Acad Sci 1993;681:325-328.
57. Reim J, McIntosh KR, Martin S, Drachman DB: Specific immunotherapeutic strategy for myasthenia gravis: targeted antigen-presenting cells. J Neuroimmunol 1992;41:61-70.
58. Roitt I, Brostoff J, Male D: Immunology, 3rd ed. St. Louis, CV Mosby Co, 1993.
59. Schwartz RH: T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex. Annu Rev Immunol 1985;3:237-261.
60. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-1356.
61. Snider DB, Segal DM: Efficiency of antigen presentation after targeting to surface IgG, IgM, FcRII, and B220 on murine on murine splenic B cells. J Immunol 143:59-65.
62. 125I-labeled receptor prevent functional damage at the neuromuscular junction? J Neuroimmunol 1985;7:97-105.
63. Thompson HS, Staines NA: Could specific oral tolerance be a therapy for autoimmune disease? Immunol Today 1990;11: 396-399.
64. Tindall RA, Phillips JT, RollinsJA, Wells L, Hall K: A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993;681:539-551.
65. Trentham DE, Dynesium-Trentham A, Orav EJ, et al.: Effects of oral administration of Type II collagen on rheumatoid arthritis. Science 1993;261:1727-1730.
66. Van der Meche FGA, Schmitz PIM: Dutch Guillain-Barre study group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain Barre syndrome. N Engl J Med 1992;326:1123-1129.
67. Vincent A: Immunology of acetylcholine receptors in relation to myasthenia gravis. Physiol Rev 1980;60:756-824.
68. Waldmann TA: The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986;232:727-732.
69. Weiner HC, MacKin GA, Matsui M, et al.: Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993;259:1321-1324.